Inscripta joins EuropaBio: delivering global biotechnology advances

EuropaBio is pleased to announce that United States-based Inscripta has joined as an associate member.

Inscripta, known as the ‘the digital genome engineering company,’ has developed the world’s first ‘benchtop biofoundry.’ The Onyx™ platform, which aims to bring genome technology breakthroughs into everyday lab use, is built on the company’s integrated CRISPR-based system which includes an instrument, consumables, software, and assays. Parallel genome engineering experiments in an automated and scalable workflow are all now accessible at the benchtop with the touch of a button.

Founded in 2015, Inscripta is now expanding its operations into Europe through a new office in Copenhagen, Denmark.

EuropaBio Director-General Dr. Claire Skentelbery says “Inscripta shows the pathway of how biotechnology is applied to accelerate R&D across all sectors. We are absolutely delighted to have the Inscripta team on board and will be working with them across our Councils for a competitive biotech sector.”

Inscripta CEO Sri Kosaraju added, “We are pleased to be joining EuropaBio and are looking forward to expanding our collaborations with the European genome engineering community. Inscripta’s goal is to empower scientists around the world with technologies that enable them to probe the genome with unprecedented breadth and speed. We believe that the Onyx platform will help usher in a new era of biological discovery and yield solutions that benefit all, such as sustainably derived materials, improved crops and better foods, and new and improved ways to treat disease.”

About the Onyx Platform

The Onyx platform is the world’s first benchtop system for scalable digital genome engineering and consists of a benchtop instrument, consumables, software and assays. With a fully automated CRISPR-based workflow, the Onyx platform enables massively parallel, trackable editing of single cells at an unprecedented scale. Customers like Sestina Bio are successfully experiencing how the Onyx platform is significantly improving the four steps of synthetic biology to accelerate forward engineering and genome discovery:

• Design genome-scale libraries with a few clicks using the InscriptaDesigner software

• Generate millions of precisely edited cells with push-button simplicity on the Onyx instrument using customized Onyx Genome Engineering Kits

• Test and characterize thousands of edits in the Onyx Cell Library with our Genotyping Assays followed by pooled or isolated phenotyping

• Learn the impact of individual edits using the same Genotyping Assays and our InscriptaResolver software

The Onyx platform is enabling customers to routinely iterate through genome engineering cycles with fewer resources, faster than was ever possible before. For more information about the Onyx platform, visit www.inscripta.com/products.

About Inscripta

Inscripta is a life science technology company whose mission is to empower researchers to realize the full potential of the bioeconomy. The company is headquartered in Boulder, Colo., with offices in San Diego and Pleasanton, Calif., and Copenhagen, Denmark. For more information, visit www.inscripta.com.